Biotech News

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nkarta (NKTX)Nkarta2026-06-25 13:46 ESTEarnings

Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamide Enrollment streamlined

Open original release

Related news

Nkarta

Nkarta is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States